SMTL ID : 7r0n.1

KRasG12C in complex with GDP and compound 2

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 1.20 Å

Oligo State

monomer

Ligands

1 x MG: MAGNESIUM ION(Non-covalent)

MG.1: 2 residues within 4Å: Chain A: S.18 Ligands: GDP.3 5 PLIP interactions: 1 interactions with chain A, 4 Ligand-Water interactions Metal complexes: A:S.18, H2O.1, H2O.2, H2O.3, H2O.4

1 x H40: ~{N}-[4-[2-bromanyl-6-(2-hydroxyethylamino)pyridin-4-yl]sulfanylphenyl]propanamide(Covalent)

H40.2: 15 residues within 4Å: Chain A: G.11, C.13, K.17, P.35, T.59, A.60, G.61, E.63, E.64, R.69, D.70, M.73, Y.97, Q.100 Ligands: GDP.3 8 PLIP interactions: 8 interactions with chain A Hydrophobic interactions: A:Y.97 Hydrogen bonds: A:K.17, A:G.61 Water bridges: A:R.69, A:R.69, A:D.70, A:Q.100 pi-Cation interactions: A:R.69

1 x GDP: GUANOSINE-5'-DIPHOSPHATE(Non-covalent)

GDP.3: 20 residues within 4Å: Chain A: A.12, C.13, G.14, V.15, G.16, K.17, S.18, A.19, F.29, D.31, Y.33, N.117, K.118, D.120, L.121, S.146, A.147, K.148 Ligands: MG.1, H40.2 21 PLIP interactions: 21 interactions with chain A Hydrogen bonds: A:G.14, A:V.15, A:G.16, A:K.17, A:S.18, A:A.19, A:D.31, A:Y.33, A:N.117, A:K.118, A:K.118, A:A.147, A:K.148 Water bridges: A:S.18, A:S.18, A:D.31, A:K.148 Salt bridges: A:K.17, A:D.120 pi-Stacking: A:F.29, A:F.29

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Weiss, A. et al., Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discov (2022)

Release Date

2022-04-27

Peptides

GTPase KRas: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

GTPase KRas

Related Entries With Identical Sequence